A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2011

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Human polyomavirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Nov 2011 Results were presented at a late-breaking session at the Annual Meeting of the American Society of Nephrology (ASN) Kidney Week 2011.
    • 15 Mar 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 15 Mar 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top